Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens. Co.'s main product candidate, sulbactam-durlobactam, is an intravenous (IV), combination of sulbactam, an IV ß-lactam antibiotic, and durlobactam, an intravenous ß-lactamase inhibitor, that Co. is developing for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Co.'s second late-stage product candidate, zoliflodacin, is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. The ETTX average annual return since 2018 is shown above.
The Average Annual Return on the ETTX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ETTX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ETTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|